BALB/c mice injected with seven 0.15-ml samples of whole rabbit serum over a 2-week period developed nonneoplastic proliferation of the extrahepatic bile duct epithelium and glandular components. Sera from other animals, including bovines, humans, pigs, goats, and chickens as well as non-serum-containing secretions such as human breast milk and bile also produced this effect. Partial purification utilizing gel filtration and affinity chromatography of the active 33-65%
gel filtration and affinity chromatography of the active 33-65% saturated ammonium sulfate precipitate of whole serum indicated that the distribution and characteristics of this glycoprotein showed some similarities with those of IgA. Chromatographically purified human IgA was administered to BALB/c mice and was found to induce bile duct proliferation identical to that seen with whole human serum. Purified human IgG and IgM had no activity. Since IgA-containing serum from BALB/c mice was inactive, it appears that heterologous IgA functions as a specific extrahepatic bile duct growth factor (BDGF) in BALB/c mice. Murine susceptibility to the growth-stimulating effect of serum was strain specific; genetic studies utilizing crosses of susceptible (BALB/c) and resistant (C57BL/10) strains of mice revealed that the ability to respond to the infusion of BDGF is inherited in a polygenic fashion.
The extrahepatic bile duct (EHBD) is a tubular structure whose lumen is lined by a single layer of epithelium. The wall, composed of loose connective tissue, contains sparsely spaced glands made up primarily of ductules with few alveolar structures at their bases, Studies in rodents have demonstrated that regeneration of luminal epithelium occurring after induced injury originates from epithelial cells lining the ductules (1) . In other experimental situations, such as that occurring after reovirus 3-induced cholangitis in mice and mechanical injury in guinea pigs, the EHBD completely reorganizes into an entirely normal duct (2, 3) . In contrast, in humans, observations over many years have demonstrated that injury to the EHBD culminates in fibrotic duct obstruction; although some regeneration attempts have been recorded, these are minimal and abortive (4) . Therefore, knowledge pertaining to the factors necessary for normal growth and regeneration in animals might suggest methods for understanding and treating a variety of human diseases marked by progressive destruction ofthe EHBD. These diseases include biliary atresia and sclerosing cholangitis.
We have previously reported that injection of rabbit sera into BALB/c mice stimulates extensive growth of the EHBD (5) . In treated animals, the outer diameter of the EHBD was 7 times larger than that of controls, and in some treated animals the central lumen of such ducts increases up to 3 times normal without concomitant obstruction. Complete postmortem examination of these animals failed to reveal other gross or histologic alterations. Neither the intrahepatic portal bile ducts nor the pancreatic ducts participated in the hyperplastic process. Subsequent studies revealed that a number of animal sera, including human, chicken, bovine, porcine, and goat also possessed this bile duct growth effect.
Initial characterization, using BALB/c mice for detecting bile duct growth factor (BDGF), revealed that it could be separated from IgG contained in the 0-33% saturated ammonium sulfate precipitate and was probably not associated with albumin, because purified bovine serum albumin was inactive in BDGF assays (5) . The 33-65% saturated ammonium sulfate precipitate of whole rabbit serum demonstrated BDGF activity that was temperature stable at 6&0C, resistant to denaturation with 1% NaDodSO4, and intact after incubation with Pronase or proteinase K. Treatment with 1% NaDodSO4 followed by incubation with proteinase K abolished activity in the previously active fraction (5) . This report describes the procedures used in identifying IgA, a secretory and serum glycosylated immunoglobulin, as a BDGF. In addition, genetic studies in heterozygous mice resulting from matings between a susceptible strain (BALB/c) and a resistant one (C57BL/10) showed that susceptibility to the growth-stimulating effect of serum is determined in a polygenic fashion.
MATERIALS AND METHODS Animals. BALB/c mice used to test BDGF activity were obtained from The Jackson Laboratory. Mice used in crossbreeding experiments, C57BL/lOScSn and BALB/cAn, were provided by F.L.
Animal Protocol. Five-to 7-week-old BALB/c mice in groups of three were injected intraperitoneally or intravenously with 0.15 ml ofthe test substance, as described below. Injections were administered three times a week for a total of seven injections, and animals were sacrificed for study 7 
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Sephadex Chromatography. The active 33-65% ammonium sulfate precipitate was dissolved in 0.15 M NaCl buffered in 0.01 M sodium phosphate, pH 6.6 (PBS), dialyzed against 1 M NaCl/0.01 M sodium phosphate buffer (PB), pH 6.6, and subjected to gel filtration in that buffer on a column (39 x 2 cm) of Sephadex G-75 (Pharmacia) run at a rate of 3 ml/hr at 40C. Approximately 0.5-ml fractions were collected with an LKB microfractionator. Pooling of consecutive fractions for injection into animals was based on protein concentration, determined by absorbance measurements at 260 and 280 nm, and identification of proteins in the collected fractions by NaDodSO4/polyacrylamide gel electrophoresis (PAGE).
Glycoprotein Affinity Chromatography. The 33-65% ammonium sulfate precipitate from rabbit serum was solubilized in PBS and dialyzed against 2 M NaCl/0.02 M Tris HCl, pH 8, prior to chromatography at room temperature on a 10-ml column containing lentil lectin coupled to Sepharose 4B (Pharmacia). After collection of the unabsorbed fraction and a wash using 100 ml of dialysis buffer, material bound to lentil lectin-Sepharose 4B was eluted with 100 ml of the dialysis buffer containing 0.1 M a-methyl mannoside. The unabsorbed and absorbed eluates were concentrated by precipitation with 65% saturated ammonium sulfate, dissolved in 3.5 ml of PBS, and extensively dialyzed in PBS before assaying for BDGF.
RESULTS
Sizing the BDGF and Its Separation from Albumin. The 33-65% ammonium sulfate precipitate of whole rabbit serum contained both albumin and BDGF activity. In an attempt to separate albumin from BDGF activity by molecular size, this serum fraction was reconstituted in PBS to one-half the original serum volume (30.7 mg of protein per ml) and 1.5 ml of this material was applied to a Sephadex G-75 column. As shown in Fig. 1 , the BDGF effect in BALB/c mice could be separated from the albumin peak, which eluted at a lower molecular mass. In the fractions most active for BDGF, there were proteins that electrophoresed at 50, 67, and 180 kDa on NaDodSO4/PAGE. The major protein in the original 33-65% ammonium sulfate precipitate, as well as in the inactive fractions after Sephadex chromatography, was albumin migrating as a 67-kDa polypeptide (Fig. 1) .
Characterization of BDGF by Glycoprotein Affinity Chromatography. The proteins in the 33-65% ammonium sulfate precipitate were fractionated on a lentil-lectin column. The material that was adsorbed to the column and eluted with a-methyl mannoside was subsequently injected into mice (1.9 mg of protein per animal); this fraction had activity equal to that of whole serum (55 mg of protein per animal) and represented a 30-fold purification. Although the nonadsorbed fraction (14 mg of protein per animal) also showed some activity, this is characteristic of the heterogeneity displayed by other glycoprotein growth factors on lectin affinity columns (6) .
Presence of BDGF in Secretions. Because of the difficulty purifying small quantities of protein growth factors from the more abundant serum proteins, other body fluids were studied for their effect on the EHBD (7) . Forty milliliters of bile with a total protein content of25 mg was dialyzed against 0.01 M PB, pH 6.6, and precipitated in 65% ammonium sulfate. The precipitate was redissolved in 2.5 ml of PBS and extensively dialyzed in the same buffer prior to animal inoculation. Each of two animals received approximately 12 mg of biliary protein and developed enlarged EHBDs equivalent to those seen with sera. Human breast milk also demonstrated BDGF activity, whereas human urine had no effect on the EHBD.
Identification of IgA as a BDGF. A summary of the data indicated that the factor under study was a high molecular BALB/c mice in vivo. BDGF activity was assessed on a scale of quartiles, with 4 representing the full effect (see Fig. 2 for examples of the scoring system used). The amount of protein in each 0.5-ml fraction collected from a Sephadex G-75 column was determined as described in the text. The protein concentration in each pooled sample was as follows: fraction 51-56, 3.5 mg of protein per mouse; fraction 57-60, 4.8 mg; fraction 61-64, 8 mg; and fraction 65-69, 4.6 mg. NaDodSO4/PAGE ofrepresentative fractions collected from the Sephadex G-75 column is shown. One-microliter samples were applied to the gel. The mobilities of standard markers are shown on the left. Although all fractions have evidence of some albumin (67-kDa protein), little BDGF activity was seen in the pools of fractions 61-69, which had the highest concentrations of albumin.
weight glycoprotein present in both serum and body secretions and, as previously determined, activity ofthe factor was resistant to proteolytic degradation (5) . As some of these properties are also characteristic of IgA, a serum and secretory protein found in the 33-65% ammonium sulfate serum fraction, we injected chromatographically purified human IgA into mice according to the protocol previously described (8) . An IgA concentration of 2.2 mg/ml, which is similar to levels in normal human serum, produced bile duct proliferation identical to that seen with whole human serum (Fig. 2  B and C) . To determine whether this was a nonspecific immunoglobulin effect, both chromatographically purified IgG (15 mg/ml) and IgM (2 mg/ml) were injected into mice. However, neither of the latter immunoglobulins had any stimulatory effect on the bile ducts of these animals ( Fig. 2 D  and E ). In addition, purified bovine serum albumin (50 mg/ml) did not cause bile duct proliferation (Fig. 2F) .
The only animal sera containing normal levels of IgA that had no effect on the bile duct of BALB/c mice were those taken from BALB/c littermates. To confirm that homologous IgA had no BDGF activity, the EHBDs of BALB/c mice carrying the s107 IgA-producing myeloma, provided by M. D. Scharff, were examined histologically; they were also found to be normal (9) . Because the normal ducts are so thin, there is difficulty orienting them in paraffin; therefore, the lumina of some normal ducts are elongated as they were cut in tangential rather than in direct cross section.
Genetics. Previous work in our laboratory has demonstrated that response to the BDGF effect of heterologous IgAcontaining sera was strain specific; BALB/c and A/J mice were strongly susceptible, whereas C57BL/10, C57BL/6, C3H, and D2.G were almost totally resistant (5) . Further genetic studies have indicated that susceptibility to this effect is dominant in F1 progeny from crosses of BALB/c and C57BL/10 mice, since these hybrids showed only a slightly less pronounced response to the treatment than did parental BALB/c mice. Studies in the segregating backcross population, (BALB/c x C57BL/10)Fl x C57BL/10, have been difficult to interpret with precision; the responses of these mice, rather than falling into relatively clear groupings of susceptible and resistant mice, have covered the continuous range between the two extremes, with no more than 25% showing maximal degrees of bile duct enlargement. This finding indicates that at least two independent genes are involved in the polymorphic response to the BDGF. This interpretation was further supported by the observation that, among the seven mouse strains of the recombinant-inbred series, CXB, mice of only one strain showed a strongly susceptible phenotype, mice of four other strains showed various degrees of intermediate susceptibility, and mice of the remaining two strains were almost totally resistant. The Proc. Natl. Acad. Sci. USA 84 (1987) Presence of Additional BDGFs in IgA-Depleted Sera. The results presented in the previous section, indicating that purified IgA contained BDGF and that susceptibility to the effect of whole serum was a multigenic trait, allowed us to examine whether there might be other serum growth factors specific for the bile ducts. We studied the effect of human serum depleted of IgA by passage over Sepharose containing bound anti-IgA antibody, as well as sera from congenitally hypogammaglobulinemic patients and fetal calf sera naturally devoid of IgA. The response to seven injections of these IgA-depleted sera revealed the presence of additional bile duct growth factor(s). The absence of IgA in these sera was confirmed by immunoblotting. In contrast to purified IgA or whole sera, which caused marked thickening of the duct due to a great increase in intramural ductules and glandular structures, IgA-depleted sera produced an effect that could not be seen grossly and consisted of a modest increase in ductules without glandular proliferation (Fig. 3) .
DISCUSSION
Our finding that sera from a wide variety of animals, when given to BALB/c mice, cause proliferation of epithelial elements in the EHBD prompted attempts to identify this protein. Gel filtration utilizing Sephadex G-75 allowed separation of the active protein from albumin, the major serum protein in the 33-65% ammonium sulfate precipitate; these data, coupled with our previous results demonstrating the lack of bile duct response to purified bovine serum albumin, led to the conclusion that the BDGF was not albumin (5). However, another prominent protein in the 33-65% ammonium sulfate precipitate is IgA (8) . Although a variety of growth factors have been described that produce proliferation of cells in tissue culture and a few others cause growth of specific tissues in animal models, the immunoglobulins have not been considered as regulatory molecules for cells not directly involved with immune function (11) . However, the characterization and purification of the BDGF were consistent with the possibility that the murine bile duct growth effect was due to IgA.
Like IgA, the BDGF is a glycosolated protein that is present in serum and mucosal secretions, including bile and breast milk (12) . Other similarities include resistance to proteolysis of the native molecule and thermal stability. Separation of proteins on Sephadex G-75 demonstrated a 50-kDa band in the active fractions, consistent with the mobility of IgA heavy chain, after reduction by mercaptoethanol in NaDodSO4. In addition, these fractions contained IgA, as demonstrated by immunoblot. Direct comparison of purified IgA with whole serum in the animal model suggests that either IgA or a factor that copurifies with it has a profound growth effect on the EHBD. Of all the sera we have tested, the only IgA-containing serum with no effect was from BALB/c mice, leading to the conclusion that heterologous IgA is an important BDGF. It is intriguing that IgA should have this specific growth effect, since the hepatobiliary tract in animals has a central role in the metabolism of circulating IgA and bile-derived IgA serves as an important source of gut immunity (13, 14) . In mice approximately 8.8 mg of plasma IgA per kg per day is removed from the circulation and excreted into bile, utilizing secretory component (SC) as a receptor (15) . In humans, this hepatobiliary secretory pathway is quantitatively less, because only 0.8 mg of circulating IgA per kg per day enters the bile.
SC is a normal constituent of the cellular membrane of a variety of murine liver cells, including hepatocytes and bile ductular epithelium as well as epithelium in the EHBDs (16) . This receptor binds J-chain-containing dimeric IgA in the circulation and transports it through the cell to the bile, where it is secreted, still bound to its ligand, as secretory IgA (17) . Although homologous IgA is processed by SC, heterologous IgA injected into rats is processed by both SC and the asialoglycoprotein (ASG) receptor (18) . This information obviously provides an attractive explanation for the different ways in which the animals responded to homologous versus heterologous serum. By analogy to the rat model, it is possible that homologous murine IgA is also transported solely by SC An alternative explanation for the response to heterologous IgA is that the active growth factor is an antibody linked to IgA. Such an antigen-(IgA)-antibody complex would be excreted by the IgA-specific mechanism if the antibody were IgG but not IgM, as the latter is too large to be processed through the SC receptor (19) . Such an explanation would explain the lag time of 2-3 weeks before both the bile duct growth effect and the putative antibody to IgA are developed.
Although the data presented implicate heterologous IgA as a potentiator of growth in the EHBD, it is unclear what form of the immunoglobulin is responsible. Monomeric IgA predominates in human serum, while the dimeric form bound to J chain predominates in rabbit serum (20) . Secretions such as breast milk and bile are highest in secretory IgA (21) . Since each of the above-mentioned substances was a potent stimulator of growth in the EHBD, further investigations are necessary to determine whether monomeric, polymeric, or secretory IgA is responsible for the effect we have noted. In addition, it will be necessary to determine whether the human subclass, IgAl or IgA2, bears any relationship to the ability of the immunoglobulin to stimulate growth.
In addition to the IgA-related growth factor, genetic studies and purification procedures have unmasked a second BDGF(s). Sera from sources in which little or no IgA is present, such as fetal calf, congenitally hypogammaglobulinemic patients, or serum processed through an affinity column with antibody to IgA linked to Sepharose, have shown some microscopic BDGF activity. Although the second factor in serum is much less active than the IgArelated BDGF, it must be further purified and characterized. The presence of a second BDGF may account for the apparent multigenic nature of the EHBD response. Further genetic studies using purified IgA in place of serum should clarify this issue.
